Ross Thibodaux, MD
Rheumatology · Thibodaux, LANPI 1447693619
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 72.7% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $9,633 and has fallen 81.7% since, to $1,761 in 2025.
Across 562 payments — averaging $53.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$22K
- AbbVie$2K
- Novartis$888
- Johnson & Johnson$681
- ANI Pharmaceuticals, Inc.$575
- UCB, Inc.$467
- plus $4K from 24 others
What the payments were for
- Speaking & faculty fees$17,51559%
- Travel & lodging$1,5545%
- Food & beverage$10,53135%
- Education$2731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 140 | $21,710 |
| AbbVie | 114 | $1,993 |
| Novartis | 51 | $888 |
| Johnson & Johnson(2 entities) | 31 | $681 |
| ANI Pharmaceuticals, Inc. | 16 | $575 |
| UCB, Inc. | 25 | $467 |
| Pfizer | 27 | $461 |
| Lilly USA, LLC | 26 | $423 |
| Mallinckrodt Hospital Products Inc. | 18 | $402 |
| GSK | 17 | $389 |
| AstraZeneca(2 entities) | 15 | $300 |
| Radius Health, Inc. | 12 | $281 |
| Aurinia Pharma U.S., Inc. | 13 | $241 |
| Sanofi | 10 | $208 |
| Mallinckrodt Enterprises LLC | 10 | $144 |
| E.r. Squibb & Sons, L.L.C. | 7 | $120 |
| Hikma Pharmaceuticals USA | 5 | $83 |
| Fresenius Kabi USA, LLC | 3 | $68 |
| Sandoz | 2 | $55 |
| Biocon Biologics Inc | 3 | $54 |
| Genentech USA, Inc. | 3 | $50 |
| Organon | 3 | $44 |
| Boehringer Ingelheim | 2 | $44 |
| Novo Nordisk | 2 | $43 |
| Sobi, Inc | 1 | $31 |
| Si-bone, Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 2 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$17,690
- EVENITY$245
- PURIFIED CORTROPHIN GEL$223
- NUCALA$133
- Enbrel$106
How this compares
$29,873 in reported general payments places this provider in the 80th percentile of 88 rheumatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 94 | $734,710 |
| RinvoqUpadacitinib | 66 | $462,481 |
| Xeljanz XrTofacitinib Citrate | 38 | $227,726 |
| OtezlaApremilast | 41 | $196,681 |
| EnbrelEtanercept | 22 | $182,576 |
| Actemra ActpenTocilizumab | 31 | $165,377 |
| Cimzia (2 Pack)Certolizumab Pegol | 24 | $136,871 |
| ProliaDenosumab | 66 | $116,842 |
| Orencia ClickjectAbatacept | 18 | $102,798 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $101,588 |
| Taltz AutoinjectorIxekizumab | 13 | $88,462 |
| KevzaraSarilumab | 18 | $77,631 |
| XeljanzTofacitinib Citrate | 17 | $71,877 |
| TymlosAbaloparatide | 22 | $59,294 |
| Teriparatide | 13 | $31,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Enbrel, Prolia | $21,710 | $496,099129 claims |
| AbbVieRinvoq | $1,993 | $462,48166 claims |
| UCB, Inc.Cimzia (2 Pack) | $467 | $136,87124 claims |
| SanofiKevzara | $208 | $77,63118 claims |
| PfizerXeljanz | $461 | $71,87717 claims |
| Radius Health, Inc.Tymlos | $281 | $59,29422 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $22 | $11,882219 claims |
| Hikma Pharmaceuticals USAMitigare | $83 | $8,02713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 88 rheumatology providers in Louisiana.
Other rheumatology in Thibodaux
- Beau BoudreauxThibodaux$11K
- Aaron BroadwellShreveport$1.6M
- Ladislas LazaroLafayette$265K
- Jerry PoundsMetairie$252K
- Carl GauthierHammond$219K
- Malik SpadyCovington$160K
- Sean ShannonBaton Rouge$157K
- Stephen LindseyBaton Rouge$130K
- Agnes SolonAlexandria$123K
- Randall BeylBaton Rouge$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.